MA52924A - Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule - Google Patents

Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Info

Publication number
MA52924A
MA52924A MA052924A MA52924A MA52924A MA 52924 A MA52924 A MA 52924A MA 052924 A MA052924 A MA 052924A MA 52924 A MA52924 A MA 52924A MA 52924 A MA52924 A MA 52924A
Authority
MA
Morocco
Prior art keywords
combinations
topical formulations
formulations including
adhesion proteins
mold adhesion
Prior art date
Application number
MA052924A
Other languages
English (en)
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of MA52924A publication Critical patent/MA52924A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA052924A 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule MA52924A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16

Publications (1)

Publication Number Publication Date
MA52924A true MA52924A (fr) 2021-04-28

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052924A MA52924A (fr) 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Country Status (12)

Country Link
US (2) US11672792B2 (fr)
EP (1) EP3648767A4 (fr)
JP (1) JP7288404B2 (fr)
KR (1) KR20200039677A (fr)
CN (3) CN115300508A (fr)
AU (1) AU2018295944B2 (fr)
CA (1) CA3068818A1 (fr)
MA (1) MA52924A (fr)
MX (1) MX2020000029A (fr)
SG (1) SG11201911841PA (fr)
TW (1) TW201919633A (fr)
WO (1) WO2019007356A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200039677A (ko) * 2017-07-05 2020-04-16 장인 무코케어 파마슈티컬 컴퍼니 리미티드 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형
CN116785447A (zh) * 2018-09-14 2023-09-22 艾缇亚(上海)制药有限公司 孟鲁司特与肽的新缀合物
WO2020143744A1 (fr) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes
AU2020344762A1 (en) * 2019-09-14 2022-04-14 Jiangyin Usun Pharmaceutical Co., Ltd. New peptides
JP2023503373A (ja) * 2019-12-02 2023-01-27 エンリティザ（シャンハイ）ファーマシューティカル カンパニー リミテッド 新規多機能オリゴペプチド
CN114929283A (zh) * 2019-12-02 2022-08-19 艾缇亚(上海)制药有限公司 肽和多糖的新缀合物
NZ790643A (en) 2020-02-03 2023-05-26 Taro Pharma Ind Topical montelukast formulations
EP4228641A1 (fr) 2020-10-13 2023-08-23 Diomed Developments Limited Formulations de gel contenant du montélukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2022193186A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux agents diagnostiques et thérapeutiques
EP4380569A1 (fr) * 2021-08-06 2024-06-12 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. Nouveau traitement du trouble de l'immunodéficience
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705320B2 (en) * 1995-12-28 1999-05-20 Welfide Corporation 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
CA2535029C (fr) * 2003-08-07 2013-07-16 Healor Ltd. Compositions pharmaceutiques et methodes permettant d'accelerer la cicatrisation de plaies
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (fr) 2006-03-30 2007-11-08 Patrin Pharma Administration nasale d'antagonistes de leukotriènes
CN1961867A (zh) 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008105803A1 (fr) * 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste du récepteur de leucotriène et utilisations associées
WO2008106081A1 (fr) 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste récepteur d'un leucotriène et leurs utilisations traiter ou prévenir la contracture capsulaire, la formation de cicatrice ou l'hyperpigmentation
WO2009137555A1 (fr) * 2008-05-06 2009-11-12 Schlesinger S Larry Formulations topiques et injectables comportant un antagoniste des récepteurs des leucotriènes et leurs utilisations
CA2653011A1 (fr) * 2008-12-03 2010-06-03 Apotex Technologies Inc Appareil et procede d'emballage et de distribution de produits pharmaceutiques
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
JP6200432B2 (ja) 2011-12-26 2017-09-20 エスケー ケミカルズ カンパニー リミテッド モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
CA2901410C (fr) * 2013-03-13 2023-09-12 Bruce Chandler May Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique
CN103655497B (zh) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
WO2017011983A1 (fr) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 Protéine de moule à action adhésive indiquée pour la protection cutanée et de l'appendice cutané
MX2018000333A (es) * 2015-07-20 2018-05-22 Bengt I Samuelsson Institute Of Life Science Res Producto de la proteina adhesiva de mejillon y las aplicaciones de este en la supresion de inflamaciones de la piel.
JP6947756B2 (ja) * 2016-02-22 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 抗菌組成物およびその使用
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
KR20200039677A (ko) * 2017-07-05 2020-04-16 장인 무코케어 파마슈티컬 컴퍼니 리미티드 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형
WO2019228307A1 (fr) * 2018-05-28 2019-12-05 Jiangyin Usun Pharmaceutical Co., Ltd. Nouvelle utilisation pharmaceutique
CN116785447A (zh) * 2018-09-14 2023-09-22 艾缇亚(上海)制药有限公司 孟鲁司特与肽的新缀合物
WO2020143744A1 (fr) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Also Published As

Publication number Publication date
MX2020000029A (es) 2020-08-06
SG11201911841PA (en) 2020-01-30
CN110312513A (zh) 2019-10-08
EP3648767A1 (fr) 2020-05-13
CA3068818A1 (fr) 2019-01-10
AU2018295944A1 (en) 2020-02-20
KR20200039677A (ko) 2020-04-16
WO2019007356A1 (fr) 2019-01-10
CN110312513B (zh) 2022-07-08
CN115300508A (zh) 2022-11-08
US20210145819A1 (en) 2021-05-20
US11672792B2 (en) 2023-06-13
JP7288404B2 (ja) 2023-06-07
JP2020527134A (ja) 2020-09-03
CN113491696A (zh) 2021-10-12
AU2018295944B2 (en) 2023-12-14
TW201919633A (zh) 2019-06-01
US20230404992A1 (en) 2023-12-21
EP3648767A4 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
MA52924A (fr) Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule
MA45600A (fr) Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées
MA49043A (fr) Formulation stable d'anticorps
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51903A (fr) Formulations d'anticorps b7-h4
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
MA54052A (fr) Formulation d'anticorps
MA46111A (fr) Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA54139A (fr) Formulation d'anticorps
ZA202101250B (en) Novel crispr-associated protein and use thereof
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
ZA201907063B (en) Insecticidal proteins and methods for their use
SG11202008044PA (en) Therapeutic anti-spla2-gib antibodies and the uses thereof
ZA202100092B (en) Modified cas9 protein and use thereof
MA48442A (fr) Structure d'extérieur
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
EP3768836A4 (fr) Modèle animal de la maladie d'alzheimer et son utilisation
CL2018001505S1 (es) Protector intimo femenino
FR3037094B1 (fr) Chassis de dormant et/ou d'ouvrant
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
MA44010A (fr) Formulations pharmaceutiques de billes comprenant du diméthylfumarate
UA39605S (uk) Стілець учнівський